These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 8400011)
1. The development of dopamine D2-receptor selective antagonists. Högberg T Drug Des Discov; 1993; 9(3-4):333-50. PubMed ID: 8400011 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand. Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586 [TBL] [Abstract][Full Text] [Related]
3. A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type. Norinder U; Högberg T Acta Pharm Nord; 1992; 4(2):73-8. PubMed ID: 1388772 [TBL] [Abstract][Full Text] [Related]
4. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners. Högberg T; Ström P; de Paulis T; Stensland B; Csöregh I; Lundin K; Hall H; Ogren SO J Med Chem; 1991 Mar; 34(3):948-55. PubMed ID: 1672158 [TBL] [Abstract][Full Text] [Related]
5. In vitro receptor binding characteristics of the new dopamine D2 antagonist [125I]NCQ-298: methodological considerations of high affinity binding. Jerning E; Malmberg A; Mohell N J Recept Signal Transduct Res; 1995; 15(1-4):503-15. PubMed ID: 8903960 [TBL] [Abstract][Full Text] [Related]
6. Syntheses of [123I]-, [125I]- and unlabelled (S)-3-iodo-5,6-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors. Högberg T; Ström P; Hall H; Köhler C; Halldin C; Farde L Acta Pharm Nord; 1990; 2(1):53-60. PubMed ID: 1971177 [TBL] [Abstract][Full Text] [Related]
7. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168 [TBL] [Abstract][Full Text] [Related]
8. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain. de Paulis T Curr Pharm Des; 2003; 9(8):673-96. PubMed ID: 12570798 [TBL] [Abstract][Full Text] [Related]
9. Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models. Högberg T; Rämsby S; de Paulis T; Stensland B; Csöregh I; Wägner A Mol Pharmacol; 1986 Oct; 30(4):345-51. PubMed ID: 2945089 [TBL] [Abstract][Full Text] [Related]
10. Potential antipsychotic agents. 7. Synthesis and antidopaminergic properties of the atypical highly potent (S)-5-bromo-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide and related compounds. A comparative study. Högberg T; de Paulis T; Johansson L; Kumar Y; Hall H; Ogren SO J Med Chem; 1990 Aug; 33(8):2305-9. PubMed ID: 1973734 [TBL] [Abstract][Full Text] [Related]
12. Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds. Ohmori J; Maeno K; Hidaka K; Nakato K; Matsumoto M; Tada S; Hattori H; Sakamoto S; Tsukamoto S; Usuda S; Mase T J Med Chem; 1996 Jul; 39(14):2764-72. PubMed ID: 8709107 [TBL] [Abstract][Full Text] [Related]
13. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. Olsson H; Halldin C; Swahn CG; Farde L J Cereb Blood Flow Metab; 1999 Oct; 19(10):1164-73. PubMed ID: 10532641 [TBL] [Abstract][Full Text] [Related]
14. Structure-selectivity investigations of D2-like receptor ligands by CoMFA and CoMSIA guiding the discovery of D3 selective PET radioligands. Salama I; Hocke C; Utz W; Prante O; Boeckler F; Hübner H; Kuwert T; Gmeiner P J Med Chem; 2007 Feb; 50(3):489-500. PubMed ID: 17266201 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145 [TBL] [Abstract][Full Text] [Related]
16. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride. Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336 [TBL] [Abstract][Full Text] [Related]